DALLAS, Dec. 2, 2020 /PRNewswire/ — Puration, Inc. (USOTC: PURA) today highlighted plans for its recently announced partnership with Alkame Holdings Inc. (USOTC: ALKM). As part of PURA’s overall hemp lifestyle brand strategy, PURA has acquired a five percent stake in ALKM as part of a strategic partnership. ALKM already bottles PURA’s EVERx CBD Sports Water and now PURA plans to substantially expand its co packing relationship with ALKM.
In January of this year, PURA launched an acquisition campaign as a forerunner initiative to the first step of its hemp lifestyle brand transition. The company leveraged its own experience and organic core competencies to acquire CBD infused beverage, edible and topical businesses.
PURA targeted CBD product acquisitions that could be enhanced with PURA’s patented technology. PURA owns a license to a U.S. Patented cannabis extraction process backed by extensive university medical research. The license, issued by NCM Biotech, is exclusive for beverages, edibles and cosmetics among other uses. NCM Biotech is focused on medical research and Puration has access to that research.
Since launching the acquisition campaign in January, the company has acquired a CBD confections business, a CBD pet products business and CBD sun care business. Combined with its existing beverage industry product line, PURA’s combined horizontal market opportunity ranges across over $2 trillion in market value:
Look for a series of updates coming soon on new PURA products to be produced by ALKM.
For more information on Puration, visit http://www.purationinc.com.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
+1 (800) 861-1350